Showing results (111-120 of 146) with videos related to
Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell CarcinomaAndrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.American Journal of Clinical Oncology|October 30, 2024
The Effect of PD-1/PD-L1 Inhibitor and Statin Combination Therapy on Overall Survival and Gastrointestinal ToxicityJay Shah, Andres Caleb Urias Rivera, Irene Jeong-Ah Lee, et al.Kidney Cancer Journal : Official Journal of the Kidney Cancer Association|November 12, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trialSusan Halabi, Qian Yang, Andrea Carmack, et al.Therapeutic Advances in Medical Oncology|July 25, 2026
A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohortYoung Kwang Chae, Rosie Sun, Sandip P Patel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip P Patel, Megan Othus, Young Kwang Chae, et al.Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancerToni K Choueiri, Robert W Ross, Susanna Jacobus, et al.Pageof 15